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Bladder cancer rarely presents clinically with a myelophthisic picture from diffuse bone marrow inﬁl-
tration especially in the absence of detectable skeletal metastases. A 75-year old man presented with
newly diagnosed urothelial cell carcinoma of the bladder. Pathology from transurethral resection of
bladder tumor demonstrated muscle-invasive disease. Pre-therapy imaging including CT abdomen/
pelvis, CXR and bone scan demonstrated liver lesions concerning for metastatic disease but no skeletal
metastases. Labs were notable for isolated thrombocytopenia, hypercalcemia and acute kidney injury
prompting hospitalization. Hematologic work-up including bone marrow aspiration and biopsy revealed
diffuse inﬁltration of the bone marrow by urothelial cancer. The case illustrates the importance of fully
investigating otherwise unexplained clinical ﬁndings in patients with clinically localized urothelial
cancer prior to curative intent surgery.
 2015 Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Skeletal metastases occur in 32e47% of patients in ante-mortem
and post-mortem series of metastatic urothelial cancer.1 Bone
metastases in bladder cancer are often osteolytic. Thrombocyto-
penia in cancer patients is often therapy related though other
coexisting etiologies should be considered including other medi-
cations, viral infections, DIC and immune thrombocytopenia (ITP).
Myelophthisis is an uncommon cause of thrombocytopenia in
metastatic epithelial cancer wherein diffuse bone marrow inﬁltra-
tion by neoplastic cells results in replacement of hematopoietic
elements in the marrow. Myelophthisis is characterized by a leu-
koerythroblastic picture in the peripheral smear with prominentCenter for Advancing Trans-
alth under Award Number
of the authors and does not
l Institutes of Health.
mprehensive Cancer Center,
article under the CC BY-NC-ND liimmature leukocytes, nucleated erythrocytes, teardrop cells
(dacryocytes) and giant platelets.
Clinical presentation
A 75 year old Caucasian man presented to his urologist for
evaluation of recent hematuria. Cystoscopy demonstrated a sessile
right lateral bladder wall tumor with some diverticular formation
around it without exophytic component. Pathology revealed
noninvasive low-grade papillary urothelial carcinoma. Urine
cytology demonstrated atypical urothelial cells. CT abdomen and
pelvis showed a 4.9  2.9  3.3 cm right postero-lateral intramural
bladder mass at the inferior edge of a bladder diverticulumwithout
evidence of metastatic disease. Repeat TURBT showed a high-grade
urothelial carcinoma invading the muscularis propria. No angio-
lymphatic invasion or divergent differentiation was identiﬁed.
Past medical history included hypertension, right bundle branch
block, obstructive sleep apnea, gastroesophageal reﬂux, benign
prostatic hypertrophy and remote history of hepatitis A. His
medication list included Enalapril, Tamsulosin, Diltiazem, MS
Contin, Norco and Docusate as needed. He had not recently received
antibiotics, heparin or non-steroidals. Family history was notablecense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. A. Axial imaging of the abdomen showing large right postero-lateral wall bladder tumor and hypodense liver lesions. B. Whole body bone scan showing mild radioisotope
uptake in the lateral right second rib and no other areas of abnormal bony uptake.
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bacco, alcohol or illicit drugs.
Complete blood count revealed platelets of 119,000 k/mm3
(decreased from 210,000 k/mm3 3 weeks earlier), white blood cell
count 7900/mm3 and hemoglobin 14.7 g/dL. Basic metabolic panel
and liver function tests were within normal limits.
When due to begin chemotherapy 12 days later, progressive
thrombocytopenia with platelets of 60,000 k/mm3 was noted.Figure 2. Histopathology of urothelial carcinoma in bone marrow biopsy (A, B) and liver (C
residual normal bone and residual normal liver indicated by yellow arrows (A, C). The tumor
and demonstrate similar morphological features in metastatic cancer within bone (B) andWhite blood cell count was 10,800/mm3 (68% neutrophils, 16%
lymphocytes, 9% monocytes, 4% myelocytes and 2% meta-
myelocytes). Hemoglobin was normal. Calcium was 12.3 mg/dL,
Creatinine 1.4 mg/dL, BUN 30; AST 87 IU/L, ALT 47 IU/L and alka-
line phosphatase 148 IU/L. CT abdomen and pelvis demonstrated 4
new right hepatic lobe lesions ranging from 0.7 to 1.3 cm con-
cerning for metastatic disease (Fig. 1A). Bone scan demonstrated
mild increased likely post-traumatic uptake in the right lateral, D). Solid nests and trabeculae of tumor cells indicated by black arrows are adjacent to
cells have pleomorphic and hyperchromatic nuclei with minimal amount of cytoplasm
liver (D). A and C, 40. B and D, 200.
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abnormality.
Hypercalcemia and acute kidney injury resolved with hydra-
tion and IV bisphosphonate. Repeat white blood cell count was
10,700/mm3, hemoglobin 13.2 g/dL, and platelets 54,000 k/mm3.
DIC work up was negative with PT 11.9, INR 1.2, PTT 31.8 and
ﬁbrinogen 507 mg/dL. Serum protein electrophoresis and urine
protein electrophoresis demonstrated glomerular proteinuria.
Hepatitis A, B, and C and HIV serologies were negative. Vitamin
B12, folic acid, TSH, serum immunoglobulins and haptoglobin
were normal.
Peripheral blood smear revealed mild anisocytosis, normal
white blood cells, no schistocytes, spherocytes or dacrocytes, and
normal-appearing but decreased number of platelets. There were
occasional giant platelets. An abdominal ultrasound demonstrated
bladder mass and multiple hypoechoic 1 cm right hepatic lobe
masses. The spleenwas 11.4 cm. Therewas concern for autoimmune
thrombocytopenia (ITP) versus inﬁltration of the marrow by met-
astatic urothelial carcinoma or less likely a primary bone marrow
disorder. He was empirically started on prednisone 1 mg/kg for
possibility of ITP without improvement. Histopathologic evaluation
of the liver biopsy was consistent with metastatic high-grade uro-
thelial carcinoma (Fig. 2).
Bonemarrow aspiration and biopsy from the iliac crest was then
performed. Bone marrow was almost completely replaced by
diffuse sheets and nests of atypical epithelial cells with high nu-
clear/cytoplasmic ratio, small nucleoli and numerous mitoses
(Fig. 2). The morphology of the epithelial cells present was identical
to that seen in the prior liver biopsy with the metastatic foci. Only a
small 2 mm focus of residual hematopoietic elements was seen.
Erythroid elements showed full spectrum of maturation with no
evidence of dysplasia. Myeloid lineage showed slight left shift in
maturation but no morphologic evidence of dysplasia. Megakar-
yocytes were decreased without atypia. Immunohistochemistry
revealed neoplastic epithelial cells diffusely and strongly positive
for cytokeratin cocktail CAM5.2 and AE1/3, focally for CK7 and did
not stain for CK5/6, p63, chromogranin A, synaptophysin, TTF1,
CD45 or TdT. CD45 stained only the residual hematopoietic
elements.
We analyzed the TURBT specimen by next generation
sequencing (liver biopsy FFPE tissue was submitted but was inad-
equate) for a targeted gene panel with capture DNA and RNASeq
(Paradigm, Ann Arbor, MI). Macro-dissection was performed and
resulted in an increase in tumor content from an estimated 35% to
approximately 60%. The Cancer Diagnostic (PCDx) Report revealed
an EGFR c.2367C>T mutation which was considered as silent and
not actionable (the ﬁnding is however 2 bases away from anactionable ﬁnding). No actionable gains in copy number variation
were seen. Messenger RNA over-expression was noted for BRCA1,
TUBB3, CAIX, survivin, TOPO2a, TS, PARP1, BAX, TP, MET, FABP5,
EZH2 and LRP6. Of note, elevations of BRCA1, TUBB3, CAIX, survivin,
PARP1 and EZH2 suggest but not determine minimal single agent
activity for platinum agents (level II-3 for BRCA1 and level II-3 for
survivin), vinca alkaloids, taxanes, and bevacizumab. High TOPO2a
suggests clinical beneﬁt for anthracyclines. Usually, an elevated TP
(thymidine phosphorylase) indicates clinical beneﬁt for ﬂuoropyr-
imidines; however, this is annulled by high TS (thymidylate syn-
thase), survivin and CAIX.
The patient received eight weekly infusions of paclitaxel but
passed away from pneumonia and sepsis. His platelet count
declined further without indication of clinical beneﬁt from
chemotherapy.Discussion
To our knowledge, this is an extremely unusual clinical pre-
sentation of urothelial cell carcinoma of the bladder diffusely
inﬁltrating the bone marrow causing isolated thrombocytopenia.
Surreptitious inﬁltration of the bone marrow may not be detected
on routine axial imaging.
Cytopenias from diffuse bonemarrow involvement by urothelial
cancer complicate the administration of optimal chemotherapy as
in this patient’s clinical course. We suspect that the unusual pattern
of metastasis could reﬂect an unusual biological variant of uro-
thelial cancer. The case also illustrates the shortcomings of
currently available commercial targeted next generation
sequencing assays for clinical use that choose a gene panel for
analysis. The detection of actionable genomic aberrations in the
tumor is only about 25e30%. The Cancer Genome Atlas Research
Network (TCGA) project and institutional studies have uncovered
multiple molecular genomic abnormalities in urothelial cancer
providing an exceptional framework to inform therapeutic
approaches.2Conﬂict of interest
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